JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2242973, encodeId=c57c22429e310, content=12.5号投稿，第2天通过技术审核，现在一直停留在“with editor”状态里的“Editor assigned”，11天了，求问最近投稿的大佬，进入下一步送审需要多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=294a8447582, createdName=ms1000000866284071, createdTime=Mon Dec 16 19:46:02 CST 2024, time=2024-12-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2138638, encodeId=c55d213863802, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：外科;综述 经验分享：4.13投稿，5.23接收。一个月多一点直接接收。特别有效率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue May 23 20:02:59 CST 2023, time=2023-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2259002, encodeId=e77c22590026b, content=为什么修回块两个月了没有任何变化。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a42b8565171, createdName=ms8000001608810099, createdTime=Thu Apr 03 17:29:43 CST 2025, time=2025-04-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2127011, encodeId=7336212e011e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：6号投稿，8号接收，19号在线发表，感谢编辑和审稿人，非常高效！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2675544063, createdName=王子安那, createdTime=Wed Apr 19 12:29:46 CST 2023, time=2023-04-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2254100, encodeId=40c52254100d9, content=偏重的研究方向：肿瘤;影像学 经验分享：一般要请几个身审稿专家啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47e45294975, createdName=148704ebm06暂无昵称, createdTime=Sat Mar 01 13:12:22 CST 2025, time=2025-03-01, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=631, replyNumber=139, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2169337, encodeId=5d54216933e1a, content=11.6就1 Reviewer report received，现在依然没有返修消息，只有一个审稿人。我看别人的都是审稿意见回来一周就有返修消息了，大家之前有遇到的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=ms8000000386451635, createdTime=Sat Nov 18 16:15:40 CST 2023, time=2023-11-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2201278, encodeId=9e2922012e80b, content=捉急的等待，不知道啥时候有结果。。。 Version 1 (private) received 11 Mar, 2024 Reviews received Received 24 Apr, 2024 Reviewers agreed On 27 Mar, 2024 Reviewers invited Invitations sent on 21 Mar, 2024 Submission checks complete On 13 Mar, 2024 Editor assigned On 13 Mar, 2024 First submitted to Journal of Cancer Research and Clinical Oncology On 11 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/05tPoOriam2U5UQB0v594rPQgFsCeTZgGbca62Lakvib8siboLpYqgE5JQQTrr5VHibHMsouLWKiaRWObHAynlYj26Q/132, createdBy=1a7c2030420, createdName=huahaha, createdTime=Tue Apr 30 16:44:27 CST 2024, time=2024-04-30, status=1, ipAttribution=广西)]

2024-12-16 ms1000000866284071 来自山东省

12.5号投稿，第2天通过技术审核，现在一直停留在“with editor”状态里的“Editor assigned”，11天了，求问最近投稿的大佬，进入下一步送审需要多长时间？

22 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2242973, encodeId=c57c22429e310, content=12.5号投稿，第2天通过技术审核，现在一直停留在“with editor”状态里的“Editor assigned”，11天了，求问最近投稿的大佬，进入下一步送审需要多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=294a8447582, createdName=ms1000000866284071, createdTime=Mon Dec 16 19:46:02 CST 2024, time=2024-12-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2138638, encodeId=c55d213863802, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：外科;综述 经验分享：4.13投稿，5.23接收。一个月多一点直接接收。特别有效率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue May 23 20:02:59 CST 2023, time=2023-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2259002, encodeId=e77c22590026b, content=为什么修回块两个月了没有任何变化。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a42b8565171, createdName=ms8000001608810099, createdTime=Thu Apr 03 17:29:43 CST 2025, time=2025-04-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2127011, encodeId=7336212e011e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：6号投稿，8号接收，19号在线发表，感谢编辑和审稿人，非常高效！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2675544063, createdName=王子安那, createdTime=Wed Apr 19 12:29:46 CST 2023, time=2023-04-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2254100, encodeId=40c52254100d9, content=偏重的研究方向：肿瘤;影像学 经验分享：一般要请几个身审稿专家啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47e45294975, createdName=148704ebm06暂无昵称, createdTime=Sat Mar 01 13:12:22 CST 2025, time=2025-03-01, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=631, replyNumber=139, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2169337, encodeId=5d54216933e1a, content=11.6就1 Reviewer report received，现在依然没有返修消息，只有一个审稿人。我看别人的都是审稿意见回来一周就有返修消息了，大家之前有遇到的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=ms8000000386451635, createdTime=Sat Nov 18 16:15:40 CST 2023, time=2023-11-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2201278, encodeId=9e2922012e80b, content=捉急的等待，不知道啥时候有结果。。。 Version 1 (private) received 11 Mar, 2024 Reviews received Received 24 Apr, 2024 Reviewers agreed On 27 Mar, 2024 Reviewers invited Invitations sent on 21 Mar, 2024 Submission checks complete On 13 Mar, 2024 Editor assigned On 13 Mar, 2024 First submitted to Journal of Cancer Research and Clinical Oncology On 11 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/05tPoOriam2U5UQB0v594rPQgFsCeTZgGbca62Lakvib8siboLpYqgE5JQQTrr5VHibHMsouLWKiaRWObHAynlYj26Q/132, createdBy=1a7c2030420, createdName=huahaha, createdTime=Tue Apr 30 16:44:27 CST 2024, time=2024-04-30, status=1, ipAttribution=广西)]

2023-05-23 胸外科小大夫来自辽宁省

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：外科;综述
经验分享：4.13投稿，5.23接收。一个月多一点直接接收。特别有效率。

140 13

展开13条回复

[GetPortalCommentsPageByObjectIdResponse(id=2242973, encodeId=c57c22429e310, content=12.5号投稿，第2天通过技术审核，现在一直停留在“with editor”状态里的“Editor assigned”，11天了，求问最近投稿的大佬，进入下一步送审需要多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=294a8447582, createdName=ms1000000866284071, createdTime=Mon Dec 16 19:46:02 CST 2024, time=2024-12-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2138638, encodeId=c55d213863802, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：外科;综述 经验分享：4.13投稿，5.23接收。一个月多一点直接接收。特别有效率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue May 23 20:02:59 CST 2023, time=2023-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2259002, encodeId=e77c22590026b, content=为什么修回块两个月了没有任何变化。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a42b8565171, createdName=ms8000001608810099, createdTime=Thu Apr 03 17:29:43 CST 2025, time=2025-04-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2127011, encodeId=7336212e011e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：6号投稿，8号接收，19号在线发表，感谢编辑和审稿人，非常高效！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2675544063, createdName=王子安那, createdTime=Wed Apr 19 12:29:46 CST 2023, time=2023-04-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2254100, encodeId=40c52254100d9, content=偏重的研究方向：肿瘤;影像学 经验分享：一般要请几个身审稿专家啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47e45294975, createdName=148704ebm06暂无昵称, createdTime=Sat Mar 01 13:12:22 CST 2025, time=2025-03-01, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=631, replyNumber=139, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2169337, encodeId=5d54216933e1a, content=11.6就1 Reviewer report received，现在依然没有返修消息，只有一个审稿人。我看别人的都是审稿意见回来一周就有返修消息了，大家之前有遇到的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=ms8000000386451635, createdTime=Sat Nov 18 16:15:40 CST 2023, time=2023-11-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2201278, encodeId=9e2922012e80b, content=捉急的等待，不知道啥时候有结果。。。 Version 1 (private) received 11 Mar, 2024 Reviews received Received 24 Apr, 2024 Reviewers agreed On 27 Mar, 2024 Reviewers invited Invitations sent on 21 Mar, 2024 Submission checks complete On 13 Mar, 2024 Editor assigned On 13 Mar, 2024 First submitted to Journal of Cancer Research and Clinical Oncology On 11 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/05tPoOriam2U5UQB0v594rPQgFsCeTZgGbca62Lakvib8siboLpYqgE5JQQTrr5VHibHMsouLWKiaRWObHAynlYj26Q/132, createdBy=1a7c2030420, createdName=huahaha, createdTime=Tue Apr 30 16:44:27 CST 2024, time=2024-04-30, status=1, ipAttribution=广西)]

2023-08-03 ms1000001633014790 来自陕西省

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤
经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵

341 37

展开37条回复

[GetPortalCommentsPageByObjectIdResponse(id=2242973, encodeId=c57c22429e310, content=12.5号投稿，第2天通过技术审核，现在一直停留在“with editor”状态里的“Editor assigned”，11天了，求问最近投稿的大佬，进入下一步送审需要多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=294a8447582, createdName=ms1000000866284071, createdTime=Mon Dec 16 19:46:02 CST 2024, time=2024-12-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2138638, encodeId=c55d213863802, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：外科;综述 经验分享：4.13投稿，5.23接收。一个月多一点直接接收。特别有效率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue May 23 20:02:59 CST 2023, time=2023-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2259002, encodeId=e77c22590026b, content=为什么修回块两个月了没有任何变化。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a42b8565171, createdName=ms8000001608810099, createdTime=Thu Apr 03 17:29:43 CST 2025, time=2025-04-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2127011, encodeId=7336212e011e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：6号投稿，8号接收，19号在线发表，感谢编辑和审稿人，非常高效！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2675544063, createdName=王子安那, createdTime=Wed Apr 19 12:29:46 CST 2023, time=2023-04-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2254100, encodeId=40c52254100d9, content=偏重的研究方向：肿瘤;影像学 经验分享：一般要请几个身审稿专家啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47e45294975, createdName=148704ebm06暂无昵称, createdTime=Sat Mar 01 13:12:22 CST 2025, time=2025-03-01, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=631, replyNumber=139, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2169337, encodeId=5d54216933e1a, content=11.6就1 Reviewer report received，现在依然没有返修消息，只有一个审稿人。我看别人的都是审稿意见回来一周就有返修消息了，大家之前有遇到的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=ms8000000386451635, createdTime=Sat Nov 18 16:15:40 CST 2023, time=2023-11-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2201278, encodeId=9e2922012e80b, content=捉急的等待，不知道啥时候有结果。。。 Version 1 (private) received 11 Mar, 2024 Reviews received Received 24 Apr, 2024 Reviewers agreed On 27 Mar, 2024 Reviewers invited Invitations sent on 21 Mar, 2024 Submission checks complete On 13 Mar, 2024 Editor assigned On 13 Mar, 2024 First submitted to Journal of Cancer Research and Clinical Oncology On 11 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/05tPoOriam2U5UQB0v594rPQgFsCeTZgGbca62Lakvib8siboLpYqgE5JQQTrr5VHibHMsouLWKiaRWObHAynlYj26Q/132, createdBy=1a7c2030420, createdName=huahaha, createdTime=Tue Apr 30 16:44:27 CST 2024, time=2024-04-30, status=1, ipAttribution=广西)]

2025-04-03 ms8000001608810099 来自山东省

为什么修回块两个月了没有任何变化。。

11 0

[GetPortalCommentsPageByObjectIdResponse(id=2242973, encodeId=c57c22429e310, content=12.5号投稿，第2天通过技术审核，现在一直停留在“with editor”状态里的“Editor assigned”，11天了，求问最近投稿的大佬，进入下一步送审需要多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=294a8447582, createdName=ms1000000866284071, createdTime=Mon Dec 16 19:46:02 CST 2024, time=2024-12-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2138638, encodeId=c55d213863802, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：外科;综述 经验分享：4.13投稿，5.23接收。一个月多一点直接接收。特别有效率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue May 23 20:02:59 CST 2023, time=2023-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2259002, encodeId=e77c22590026b, content=为什么修回块两个月了没有任何变化。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a42b8565171, createdName=ms8000001608810099, createdTime=Thu Apr 03 17:29:43 CST 2025, time=2025-04-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2127011, encodeId=7336212e011e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：6号投稿，8号接收，19号在线发表，感谢编辑和审稿人，非常高效！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2675544063, createdName=王子安那, createdTime=Wed Apr 19 12:29:46 CST 2023, time=2023-04-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2254100, encodeId=40c52254100d9, content=偏重的研究方向：肿瘤;影像学 经验分享：一般要请几个身审稿专家啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47e45294975, createdName=148704ebm06暂无昵称, createdTime=Sat Mar 01 13:12:22 CST 2025, time=2025-03-01, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=631, replyNumber=139, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2169337, encodeId=5d54216933e1a, content=11.6就1 Reviewer report received，现在依然没有返修消息，只有一个审稿人。我看别人的都是审稿意见回来一周就有返修消息了，大家之前有遇到的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=ms8000000386451635, createdTime=Sat Nov 18 16:15:40 CST 2023, time=2023-11-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2201278, encodeId=9e2922012e80b, content=捉急的等待，不知道啥时候有结果。。。 Version 1 (private) received 11 Mar, 2024 Reviews received Received 24 Apr, 2024 Reviewers agreed On 27 Mar, 2024 Reviewers invited Invitations sent on 21 Mar, 2024 Submission checks complete On 13 Mar, 2024 Editor assigned On 13 Mar, 2024 First submitted to Journal of Cancer Research and Clinical Oncology On 11 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/05tPoOriam2U5UQB0v594rPQgFsCeTZgGbca62Lakvib8siboLpYqgE5JQQTrr5VHibHMsouLWKiaRWObHAynlYj26Q/132, createdBy=1a7c2030420, createdName=huahaha, createdTime=Tue Apr 30 16:44:27 CST 2024, time=2024-04-30, status=1, ipAttribution=广西)]

2023-04-19 王子安那来自天津

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：临床
经验分享：6号投稿，8号接收，19号在线发表，感谢编辑和审稿人，非常高效！

79 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=2242973, encodeId=c57c22429e310, content=12.5号投稿，第2天通过技术审核，现在一直停留在“with editor”状态里的“Editor assigned”，11天了，求问最近投稿的大佬，进入下一步送审需要多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=294a8447582, createdName=ms1000000866284071, createdTime=Mon Dec 16 19:46:02 CST 2024, time=2024-12-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2138638, encodeId=c55d213863802, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：外科;综述 经验分享：4.13投稿，5.23接收。一个月多一点直接接收。特别有效率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue May 23 20:02:59 CST 2023, time=2023-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2259002, encodeId=e77c22590026b, content=为什么修回块两个月了没有任何变化。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a42b8565171, createdName=ms8000001608810099, createdTime=Thu Apr 03 17:29:43 CST 2025, time=2025-04-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2127011, encodeId=7336212e011e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：6号投稿，8号接收，19号在线发表，感谢编辑和审稿人，非常高效！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2675544063, createdName=王子安那, createdTime=Wed Apr 19 12:29:46 CST 2023, time=2023-04-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2254100, encodeId=40c52254100d9, content=偏重的研究方向：肿瘤;影像学 经验分享：一般要请几个身审稿专家啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47e45294975, createdName=148704ebm06暂无昵称, createdTime=Sat Mar 01 13:12:22 CST 2025, time=2025-03-01, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=631, replyNumber=139, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2169337, encodeId=5d54216933e1a, content=11.6就1 Reviewer report received，现在依然没有返修消息，只有一个审稿人。我看别人的都是审稿意见回来一周就有返修消息了，大家之前有遇到的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=ms8000000386451635, createdTime=Sat Nov 18 16:15:40 CST 2023, time=2023-11-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2201278, encodeId=9e2922012e80b, content=捉急的等待，不知道啥时候有结果。。。 Version 1 (private) received 11 Mar, 2024 Reviews received Received 24 Apr, 2024 Reviewers agreed On 27 Mar, 2024 Reviewers invited Invitations sent on 21 Mar, 2024 Submission checks complete On 13 Mar, 2024 Editor assigned On 13 Mar, 2024 First submitted to Journal of Cancer Research and Clinical Oncology On 11 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/05tPoOriam2U5UQB0v594rPQgFsCeTZgGbca62Lakvib8siboLpYqgE5JQQTrr5VHibHMsouLWKiaRWObHAynlYj26Q/132, createdBy=1a7c2030420, createdName=huahaha, createdTime=Tue Apr 30 16:44:27 CST 2024, time=2024-04-30, status=1, ipAttribution=广西)]

2025-03-01 148704ebm06暂无昵称来自河北省

偏重的研究方向：肿瘤;影像学
经验分享：一般要请几个身审稿专家啊

20 0

[GetPortalCommentsPageByObjectIdResponse(id=2242973, encodeId=c57c22429e310, content=12.5号投稿，第2天通过技术审核，现在一直停留在“with editor”状态里的“Editor assigned”，11天了，求问最近投稿的大佬，进入下一步送审需要多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=294a8447582, createdName=ms1000000866284071, createdTime=Mon Dec 16 19:46:02 CST 2024, time=2024-12-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2138638, encodeId=c55d213863802, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：外科;综述 经验分享：4.13投稿，5.23接收。一个月多一点直接接收。特别有效率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue May 23 20:02:59 CST 2023, time=2023-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2259002, encodeId=e77c22590026b, content=为什么修回块两个月了没有任何变化。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a42b8565171, createdName=ms8000001608810099, createdTime=Thu Apr 03 17:29:43 CST 2025, time=2025-04-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2127011, encodeId=7336212e011e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：6号投稿，8号接收，19号在线发表，感谢编辑和审稿人，非常高效！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2675544063, createdName=王子安那, createdTime=Wed Apr 19 12:29:46 CST 2023, time=2023-04-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2254100, encodeId=40c52254100d9, content=偏重的研究方向：肿瘤;影像学 经验分享：一般要请几个身审稿专家啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47e45294975, createdName=148704ebm06暂无昵称, createdTime=Sat Mar 01 13:12:22 CST 2025, time=2025-03-01, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=631, replyNumber=139, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2169337, encodeId=5d54216933e1a, content=11.6就1 Reviewer report received，现在依然没有返修消息，只有一个审稿人。我看别人的都是审稿意见回来一周就有返修消息了，大家之前有遇到的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=ms8000000386451635, createdTime=Sat Nov 18 16:15:40 CST 2023, time=2023-11-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2201278, encodeId=9e2922012e80b, content=捉急的等待，不知道啥时候有结果。。。 Version 1 (private) received 11 Mar, 2024 Reviews received Received 24 Apr, 2024 Reviewers agreed On 27 Mar, 2024 Reviewers invited Invitations sent on 21 Mar, 2024 Submission checks complete On 13 Mar, 2024 Editor assigned On 13 Mar, 2024 First submitted to Journal of Cancer Research and Clinical Oncology On 11 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/05tPoOriam2U5UQB0v594rPQgFsCeTZgGbca62Lakvib8siboLpYqgE5JQQTrr5VHibHMsouLWKiaRWObHAynlYj26Q/132, createdBy=1a7c2030420, createdName=huahaha, createdTime=Tue Apr 30 16:44:27 CST 2024, time=2024-04-30, status=1, ipAttribution=广西)]

2020-06-12 ms5502585941462392

9月28投稿，10月7日直接接收，还以为是拒稿。😀

631 139

展开139条回复

[GetPortalCommentsPageByObjectIdResponse(id=2242973, encodeId=c57c22429e310, content=12.5号投稿，第2天通过技术审核，现在一直停留在“with editor”状态里的“Editor assigned”，11天了，求问最近投稿的大佬，进入下一步送审需要多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=294a8447582, createdName=ms1000000866284071, createdTime=Mon Dec 16 19:46:02 CST 2024, time=2024-12-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2138638, encodeId=c55d213863802, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：外科;综述 经验分享：4.13投稿，5.23接收。一个月多一点直接接收。特别有效率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue May 23 20:02:59 CST 2023, time=2023-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2259002, encodeId=e77c22590026b, content=为什么修回块两个月了没有任何变化。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a42b8565171, createdName=ms8000001608810099, createdTime=Thu Apr 03 17:29:43 CST 2025, time=2025-04-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2127011, encodeId=7336212e011e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：6号投稿，8号接收，19号在线发表，感谢编辑和审稿人，非常高效！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2675544063, createdName=王子安那, createdTime=Wed Apr 19 12:29:46 CST 2023, time=2023-04-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2254100, encodeId=40c52254100d9, content=偏重的研究方向：肿瘤;影像学 经验分享：一般要请几个身审稿专家啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47e45294975, createdName=148704ebm06暂无昵称, createdTime=Sat Mar 01 13:12:22 CST 2025, time=2025-03-01, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=631, replyNumber=139, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2169337, encodeId=5d54216933e1a, content=11.6就1 Reviewer report received，现在依然没有返修消息，只有一个审稿人。我看别人的都是审稿意见回来一周就有返修消息了，大家之前有遇到的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=ms8000000386451635, createdTime=Sat Nov 18 16:15:40 CST 2023, time=2023-11-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2201278, encodeId=9e2922012e80b, content=捉急的等待，不知道啥时候有结果。。。 Version 1 (private) received 11 Mar, 2024 Reviews received Received 24 Apr, 2024 Reviewers agreed On 27 Mar, 2024 Reviewers invited Invitations sent on 21 Mar, 2024 Submission checks complete On 13 Mar, 2024 Editor assigned On 13 Mar, 2024 First submitted to Journal of Cancer Research and Clinical Oncology On 11 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/05tPoOriam2U5UQB0v594rPQgFsCeTZgGbca62Lakvib8siboLpYqgE5JQQTrr5VHibHMsouLWKiaRWObHAynlYj26Q/132, createdBy=1a7c2030420, createdName=huahaha, createdTime=Tue Apr 30 16:44:27 CST 2024, time=2024-04-30, status=1, ipAttribution=广西)]

2023-05-13 wwei0125 来自山东省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志

194 31

展开31条回复

[GetPortalCommentsPageByObjectIdResponse(id=2242973, encodeId=c57c22429e310, content=12.5号投稿，第2天通过技术审核，现在一直停留在“with editor”状态里的“Editor assigned”，11天了，求问最近投稿的大佬，进入下一步送审需要多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=294a8447582, createdName=ms1000000866284071, createdTime=Mon Dec 16 19:46:02 CST 2024, time=2024-12-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2138638, encodeId=c55d213863802, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：外科;综述 经验分享：4.13投稿，5.23接收。一个月多一点直接接收。特别有效率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue May 23 20:02:59 CST 2023, time=2023-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2259002, encodeId=e77c22590026b, content=为什么修回块两个月了没有任何变化。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a42b8565171, createdName=ms8000001608810099, createdTime=Thu Apr 03 17:29:43 CST 2025, time=2025-04-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2127011, encodeId=7336212e011e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：6号投稿，8号接收，19号在线发表，感谢编辑和审稿人，非常高效！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2675544063, createdName=王子安那, createdTime=Wed Apr 19 12:29:46 CST 2023, time=2023-04-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2254100, encodeId=40c52254100d9, content=偏重的研究方向：肿瘤;影像学 经验分享：一般要请几个身审稿专家啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47e45294975, createdName=148704ebm06暂无昵称, createdTime=Sat Mar 01 13:12:22 CST 2025, time=2025-03-01, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=631, replyNumber=139, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2169337, encodeId=5d54216933e1a, content=11.6就1 Reviewer report received，现在依然没有返修消息，只有一个审稿人。我看别人的都是审稿意见回来一周就有返修消息了，大家之前有遇到的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=ms8000000386451635, createdTime=Sat Nov 18 16:15:40 CST 2023, time=2023-11-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2201278, encodeId=9e2922012e80b, content=捉急的等待，不知道啥时候有结果。。。 Version 1 (private) received 11 Mar, 2024 Reviews received Received 24 Apr, 2024 Reviewers agreed On 27 Mar, 2024 Reviewers invited Invitations sent on 21 Mar, 2024 Submission checks complete On 13 Mar, 2024 Editor assigned On 13 Mar, 2024 First submitted to Journal of Cancer Research and Clinical Oncology On 11 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/05tPoOriam2U5UQB0v594rPQgFsCeTZgGbca62Lakvib8siboLpYqgE5JQQTrr5VHibHMsouLWKiaRWObHAynlYj26Q/132, createdBy=1a7c2030420, createdName=huahaha, createdTime=Tue Apr 30 16:44:27 CST 2024, time=2024-04-30, status=1, ipAttribution=广西)]

2023-11-18 ms8000000386451635 来自广东省

11.6就1 Reviewer report received，现在依然没有返修消息，只有一个审稿人。我看别人的都是审稿意见回来一周就有返修消息了，大家之前有遇到的吗？

76 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2242973, encodeId=c57c22429e310, content=12.5号投稿，第2天通过技术审核，现在一直停留在“with editor”状态里的“Editor assigned”，11天了，求问最近投稿的大佬，进入下一步送审需要多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=294a8447582, createdName=ms1000000866284071, createdTime=Mon Dec 16 19:46:02 CST 2024, time=2024-12-16, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2138638, encodeId=c55d213863802, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：外科;综述 经验分享：4.13投稿，5.23接收。一个月多一点直接接收。特别有效率。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Tue May 23 20:02:59 CST 2023, time=2023-05-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2151188, encodeId=6f3b215118896, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：Part 1 审稿流程 Part 2 论坛常见问题审稿流程如下： 2023-06-20 投稿 2023-06-20 技术检查通过，安排审稿人 2023-06-23 第一个审稿人接受审稿 2023-06-25 第二个审稿人接受审稿 2023-07-01 第一个审稿意见已回 2023-07-07 第二个审稿意见已回 2023-07-09 编辑汇总意见建议小修 2023-07-13 提交返修 2023-07-25 接受后续包括编辑初步校对，选择OA还是非OA，最后校对都是在2、3天内完成，效率很高常见问题 1、文章参考格式：Endnote APA 6th（稍微参考一下既往杂志文章都不会问出这问题） 2、投稿状态的顺序：Under review（稿件进入投稿流程）→Reviewer Accepted（有审稿人开始审你的稿件了）→Reviews report received（编辑收到了审稿人的意见）→Reviewer reports received/ Ready for editor' s decision（所有的审稿人意见都回来之后，才会开始进入编辑审查阶段，等待编辑汇总意见之后会发给你对文章的处理决定） 3、回顾性研究，case report，基础，生信，meta都收录，被秒拒的大多是优先级不够或者没有任何亮点，纯生信不加试验没有亮点凭啥接收呢？杂志审稿人态度还是很端正的，结合审稿意见来看对文章的大方向和细节都是有要求的，没有给人不专业和水分较深的感觉 4、不建议文章在未发布前共享到Research Square平台上，在投稿时把那个选项X掉比较好 5、杂志可以共同通讯，在文章中标注清楚即可 6、在进入审稿流程后，所有的文章动态更新都只有通讯作者邮箱才能收到，第一作者如需及时了解动态建议勤登网站查看进程 7、OA和非OA在后续文章处理上没有任何区别，OA文章在增加引用量上有其固有优势，掏钱发文章这种事见仁见智，btw这个杂志APC偏贵, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=341, replyNumber=37, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f0b56493364, createdName=ms1000001633014790, createdTime=Thu Aug 03 23:00:50 CST 2023, time=2023-08-03, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2259002, encodeId=e77c22590026b, content=为什么修回块两个月了没有任何变化。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a42b8565171, createdName=ms8000001608810099, createdTime=Thu Apr 03 17:29:43 CST 2025, time=2025-04-03, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2127011, encodeId=7336212e011e9, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：临床 经验分享：6号投稿，8号接收，19号在线发表，感谢编辑和审稿人，非常高效！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f2675544063, createdName=王子安那, createdTime=Wed Apr 19 12:29:46 CST 2023, time=2023-04-19, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2254100, encodeId=40c52254100d9, content=偏重的研究方向：肿瘤;影像学 经验分享：一般要请几个身审稿专家啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47e45294975, createdName=148704ebm06暂无昵称, createdTime=Sat Mar 01 13:12:22 CST 2025, time=2025-03-01, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=602136, encodeId=8589602136d1, content=9月28投稿，10月7日直接接收，还以为是拒稿。😀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=631, replyNumber=139, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKVvMIdBzydxvTLf3L1GaeshlhhObuunGflfr3g7nIWDic7gMA3qJtibSju8JlxIfgk7ctQllMfqFBA/132, createdBy=edd72312792, createdName=ms5502585941462392, createdTime=Fri Jun 12 22:03:58 CST 2020, time=2020-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2133642, encodeId=0f3e21336426b, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：5.2投稿，5.4技术审查通过；5.4under review；5.9小修，5.11修回，5.12技术审查通过；5.13接收。效率极高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=31, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d09f88778, createdName=wwei0125, createdTime=Sat May 13 21:32:57 CST 2023, time=2023-05-13, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2169337, encodeId=5d54216933e1a, content=11.6就1 Reviewer report received，现在依然没有返修消息，只有一个审稿人。我看别人的都是审稿意见回来一周就有返修消息了，大家之前有遇到的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=ms8000000386451635, createdTime=Sat Nov 18 16:15:40 CST 2023, time=2023-11-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2201278, encodeId=9e2922012e80b, content=捉急的等待，不知道啥时候有结果。。。 Version 1 (private) received 11 Mar, 2024 Reviews received Received 24 Apr, 2024 Reviewers agreed On 27 Mar, 2024 Reviewers invited Invitations sent on 21 Mar, 2024 Submission checks complete On 13 Mar, 2024 Editor assigned On 13 Mar, 2024 First submitted to Journal of Cancer Research and Clinical Oncology On 11 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/05tPoOriam2U5UQB0v594rPQgFsCeTZgGbca62Lakvib8siboLpYqgE5JQQTrr5VHibHMsouLWKiaRWObHAynlYj26Q/132, createdBy=1a7c2030420, createdName=huahaha, createdTime=Tue Apr 30 16:44:27 CST 2024, time=2024-04-30, status=1, ipAttribution=广西)]

2024-04-30 huahaha 来自广西

捉急的等待，不知道啥时候有结果。。。
Version 1 (private)
received 11 Mar, 2024

Reviews received
Received 24 Apr, 2024
Reviewers agreed
On 27 Mar, 2024
Reviewers invited
Invitations sent on 21 Mar, 2024
Submission checks complete
On 13 Mar, 2024
Editor assigned
On 13 Mar, 2024
First submitted to Journal of Cancer Research and Clinical Oncology
On 11 Mar, 2024

125 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务